Moclobemide
Moclobemide is a reversible inhibitor of MAO-A that exhibits antidepressant, anti-inflammatory, antinociceptive, and neuromodulatory activities. Moclobemide decreases immobility time in animals undergoing the forced swim test and suppresses LPS-induced increases in IL-1β and TNF-α expression in glial cells. Additionally, moclobemide increases latency time in animal models of thermal pain through an α2-adrenergic receptor-mediated pathway. Moclobemide also induces hippocampal neurogenesis, upregulating progenitor cell proliferation and expression of BDNF in vitro.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18945690
| Cas No. |
71320-77-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C13H17ClN2O2 |
| Formula Wt. |
268.74 |
| IUPAC Name |
4-chloro-N-(2-morpholin-4-ylethyl)benzamide |
| Appearance |
White to off white powder |
Bielecka AM, Paul-Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 2010 Dec;382(5-6):409-17. PMID: 20811738.
Li YF, Zhang YZ, Liu YQ, et al. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004 Nov;25(11):1408-12. PMID: 15525460.
Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett. 1998 Sep 11;253(3):183-6. PMID: 9792241.
Ferigolo M, Barros HM, Marquardt AR, et al. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming. Pharmacol Biochem Behav. 1998 Jun;60(2):431-7. PMID: 9632226.
